ASH 2024 | Three-year update on the EPCORE NHL-1 trial of epcoritamab in R/R DLBCL

The Epcore NHL-1 trial was epcoritamab that was given for patients with multi-relapsed diffuse large B-cell lymphoma. And this was the three-year update that was presented. This is relapsed/refractory patients. They had to have at least two prior therapies, and many patients had had a lot more than that. Epcoritamab, the bispecific antibody, was given subcutaneously in 28-day cycles and it was given until disease progression or unacceptable toxicity. So with this three-year follow-up, 41% of patients overall had a complete remission and the median follow-up was 37.1 months in this particular study. The patients as far as median progression-free survival was 37.3 months. Overall survival for the overall population. Complete responders had not been met at the time of the analysis. Overall, it was 18.5 months. But 53% of patients remained progression-free, and 75% of patients had not initiated another therapy for relapsed lymphoma. For toxicity, the cytokine release syndrome, there was only 3% grade 3 cytokine release syndrome, and lower percentages of grade one and two. The cytopenias was about 27% between weeks one to eight and very small after that time period. So this is really showing that patients particularly who became MRD negative, which was about half of the 119 patients, could not have detectable MRD negativity. And there was a very strong correlation between getting MRD negativity and those patients that were staying in remission, which would be expected. So these are very heavily pretreated patients that had minimal mild side effects and a high percentage of patients that were still in remission, alive, doing well, and MRD negative at the three-year follow-up. So very, very exciting data.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.